MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the
issuance of pre-funded...
$175,000K
Proceeds from the
issuance of common stock...
$149,999K
Proceeds from the
issuance of common stock...
$108,101K
Proceeds from the
issuance of common stock...
$70,106K
Proceeds from stock
option exercises and...
$2,180K
Net cash provided by
financing activities
$503,807K
Canceled cashflow
$1,579K
Net increase in
cash, cash...
$312,292K
Canceled cashflow
$191,515K
Payment of issuance
costs related to...
$1,325K
Withholding of shares for tax
withholdings upon vesting of...
$254K
Change in fair value of
warrant liabilities
$334,358K
Issuance of pre-funded
warrants in connection...
$177,377K
Stock-based compensation
$18,912K
Accounts payable and
accrued liabilities
$10,930K
Non-cash lease expense
$5,647K
Loss (gain) on sale of
property and equipment
-$3,303K
Depreciation expense
$2,887K
Prepaid expenses and
other current assets
-$1,684K
Transaction costs for
issuance of pre-funded...
$643K
Proceeds from maturities
of marketable...
$5,000K
Proceeds from sales of
property and equipment
$799K
Net cash used in
operating activities
-$142,713K
Net cash (used in)
provided by investing...
-$48,802K
Canceled cashflow
$555,741K
Canceled cashflow
$5,799K
Net loss
-$695,981K
Purchases of marketable
securities
$53,660K
Operating lease
liabilities
-$2,406K
Interest amortization on
marketable securities
$67K
Purchases of property and
equipment
$941K
Segment expenses
$695,981K
Back
Back
Cash Flow
source: myfinsight.com
Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. (VOR)